Superiority of intracoronary papaverine to radiographic contrast for measuring coronary flow reserve in patients with ischemic heart disease.
Measurement of coronary flow reserve has been suggested as an adjunct to anatomic assessment of coronary stenoses in patients with ischemic heart disease. We compared papaverine hydrochloride and radiographic contrast to determine which agent was superior for the determination of coronary flow reserve. Coronary flow reserve was determined during cardiac catheterization by means of digital coronary angiography and parametric imaging. Two groups of patients were studied. Among patients in group 1, coronary flow reserve was determined by means of both papaverine and contrast. In group 1 patients with normal coronary arteries, papaverine-induced flow reserve was greater than contrast-induced reserve in all but one vascular region (n = 9, 4.98 +/- 1.15 vs 3.56 +/- 0.89; p = 0.29). Group 1 patients with coronary disease also demonstrated significantly greater flow reserve with papaverine (n = 25, 2.57 +/- 0.20 vs 1.83 +/- 0.11, p less than 0.01). Group 2 included patients with single-vessel coronary artery stenoses. These patients were studied by means of either papaverine or contrast to determine coronary flow reserve for both the stenotic "ischemic" region and an adjacent nonstenotic, "nonischemic" region. Those patients in group 2 who were studied by means of contrast had a modest difference between flow reserve values in the nonischemic and those in the ischemic regions (n = 15, 1.78 +/- 0.10 vs 1.26 +/- 0.09; p less than .0001) with considerable overlap. Patients studied by means of papaverine had a much greater separation in flow reserve between nonischemic and ischemic regions (n = 22, 2.78 +/- 0.19 vs 1.46 +/- 0.14; p less than 0.0001).(ABSTRACT TRUNCATED AT 250 WORDS)
Hodgson
J M
JM
Division of Cardiology, Rhode Island Hospital, Providence 02902.
Williams
D O
DO
D001783:Blood Flow Velocity / Q000187:drug effects; D006328:Cardiac Catheterization; D002933:Cineradiography; D003287:Contrast Media / Q000008:administration & dosage*; D017023:Coronary Angiography; D003326:Coronary Circulation; D003327:Coronary Disease / Q000175:diagnosis* / Q000503:physiopathology; D003973:Diatrizoate; D003974:Diatrizoate Meglumine; D004338:Drug Combinations; D004341:Drug Evaluation; D006801:Humans; D006940:Hyperemia / Q000139:chemically induced; D010208:Papaverine / Q000008:administration & dosage; D012189:Retrospective Studies
D003287:Contrast Media; D004338:Drug Combinations; D003973:Diatrizoate; D003974:Diatrizoate Meglumine; C027278:urovision; D010208:Papaverine